Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367441 | 1.00 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL30838803 | 0.98 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL3974202 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL22830483 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL30788403 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL19778900 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL323982 | 0.74 | ALDH1A1 (0.52) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL2493987 | 0.74 | BRD4 (0.51) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL1165562 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL29804946 | 0.74 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792260-B1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2024-09-11 | — | — | EP | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| CN-118063491-A | Imide catalyst auxiliary agent, polyimide film and preparation method | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| WO-2018134148-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| US-8541567-B2 | Transition state structure of 5′-methylthioadenosine/s-adenosylhomocysteine nucleosidases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20030144501-A1 | Conformationally constrained L-nucleosides | ISIS PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| US-5639867-A | TTTr as protective group in nucleotide synthesis | CIBA GEIGY CORPORATION (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | disclosed |
| EP-0644196-A1 | TTTr as a protecting group in nucleotide synthesis | CIBA-GEIGY AG (CH) | 1995-03-22 | — | — | EP | disclosed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | disclosed |
| US-5268464-A | Process for the preparation of nucleosides | CIBA-GEIGY CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0563010-A2 | Method of preparation of nucleosides | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144501-A1 | Conformationally constrained L-nucleosides | NSUN2, DCK, DCTD | PI4KA 2216/4885PI4K2B 2099/4885PI4K2A 2384/4885 |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | PI4KA 152/4885PI4K2B 176/4885PI4K2A 137/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | PI4KA 1642/4885PI4K2B 2022/4885PI4K2A 2259/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.